GO:0009384 N-acylmannosamine kinase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0009384 N-acylmannosamine kinase activity catalyzes the ATP-dependent phosphorylation of N-acyl-D-mannosamine to N-acyl-D-mannosamine 6-phosphate.
• In humans, this activity is carried by the C-terminal kinase domain of the bifunctional enzyme UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase (GNE), a key enzyme in sialic acid biosynthesis.
• The kinase domain can be selectively inactivated by site-directed mutagenesis without abolishing the epimerase activity, demonstrating independent domain functions.
• Crystal structures of N-acetylmannosamine kinase from human and bacterial sources have revealed the active-site architecture and provided a basis for inhibitor design.
• GNE mutations that impair kinase activity are associated with hereditary inclusion body myopathy and other sialylation disorders.
• Small-molecule inhibitors targeting N-acetylmannosamine kinase have been developed, offering tools for chemical biology and potential therapeutic leads.
Description
N-acylmannosamine kinase activity (GO:0009384) is a molecular function defined as the catalysis of the reaction ATP + N-acyl-D-mannosamine = ADP + N-acyl-D-mannosamine 6-phosphate. This phosphorylation step is essential for the activation of N-acetylmannosamine (ManNAc) prior to its conversion into sialic acid, a terminal sugar on many glycoproteins and glycolipids. In humans, the kinase activity resides in the C-terminal domain of the bifunctional enzyme UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase (GNE), which also catalyzes the preceding epimerization step. The importance of this activity is underscored by its evolutionary conservation and its involvement in diseases such as hereditary inclusion body myopathy. Researchers study N-acylmannosamine kinase activity to understand sialic acid metabolism, to develop inhibitors, and to model human disorders linked to defective sialylation.
N-acylmannosamine kinase activity At A Glance
| GO ID | GO:0009384 |
|---|---|
| GO term | N-acylmannosamine kinase activity |
| Ontology | molecular_function |
| Synonym | N-acetylmannosamine kinase activity; acetylamidodeoxymannokinase activity; ATP:N-acyl-D-mannosamine 6-phosphotransferase activity |
| Major function | Phosphorylation of N-acyl-D-mannosamine to N-acyl-D-mannosamine 6-phosphate using ATP |
| Reaction | ATP + N-acyl-D-mannosamine = ADP + N-acyl-D-mannosamine 6-phosphate |
| Human gene | GNE (UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase) |
| Cellular context | Cytosol; part of sialic acid biosynthesis pathway |
| Related diseases | Hereditary inclusion body myopathy, sialuria, and other sialylation disorders |
What Is GO:0009384?
N-acylmannosamine kinase activity (GO:0009384) is the enzymatic transfer of a phosphate group from ATP to N-acyl-D-mannosamine, yielding ADP and N-acyl-D-mannosamine 6-phosphate. This activity is synonymous with acetylamidodeoxymannokinase, acetylmannosamine kinase, acylaminodeoxymannokinase, acylmannosamine kinase, and ATP:N-acetylmannosamine 6-phosphotransferase. It is a molecular function that enables cells to phosphorylate ManNAc derivatives, a prerequisite for their further metabolism in sialic acid biosynthesis.
Why Is N-acylmannosamine kinase activity Important in Cell Biology?
N-acylmannosamine kinase activity is a critical step in the sialic acid biosynthetic pathway, controlling the flux of ManNAc into N-acetylneuraminic acid (Neu5Ac). Because sialic acids are essential for cell-cell recognition, signaling, and immune modulation, perturbations in this kinase activity can have profound physiological consequences. The bifunctional GNE enzyme is the rate-limiting step in sialic acid production, and its kinase domain is a target for small-molecule inhibitors and for understanding disease mechanisms.
• Provides the phosphorylated substrate for subsequent sialic acid synthesis.
• Mutations in GNE kinase domain cause hereditary inclusion body myopathy.
• Involved in sialuria, a disorder of sialic acid overproduction.
• Target for small-molecule inhibitors with potential therapeutic applications.
• Essential for proper glycosylation of cell surface proteins and lipids.
• Studied in bacterial pathogens for sialic acid scavenging and utilization.
• Regulated by phosphorylation via protein kinase C.
• Domain-specific functions allow selective inactivation for mechanistic studies.
• Crystal structures enable rational drug design.
• Key enzyme for metabolic engineering of sialylated biotherapeutics.
Molecular Mechanism of N-acylmannosamine kinase activity
Substrate binding and specificity
In simple terms: The enzyme grabs N-acetylmannosamine and ATP, positioning them for phosphate transfer.
N-acylmannosamine kinase binds N-acyl-D-mannosamine (e.g., N-acetylmannosamine) and ATP in a sequential manner. Structural studies of the human GNE kinase domain and bacterial homologs reveal a conserved active site that accommodates the N-acyl group and the mannosamine moiety. The enzyme exhibits specificity for N-acyl derivatives, with N-acetylmannosamine being the preferred substrate.
Catalytic mechanism
In simple terms: ATP donates a phosphate to the sugar, forming a phosphorylated product.
The kinase transfers the gamma-phosphate of ATP to the hydroxyl group at the 6-position of N-acyl-D-mannosamine, producing N-acyl-D-mannosamine 6-phosphate and ADP. This reaction requires divalent metal ions, typically Mg2+, for ATP coordination. Site-directed mutagenesis has identified residues critical for catalysis, and selective loss of kinase activity can be achieved without affecting the epimerase domain.
Domain architecture and bifunctionality
In simple terms: In humans, the kinase is part of a two-in-one enzyme that also does a preceding step.
The human GNE protein consists of an N-terminal epimerase domain and a C-terminal kinase domain. The kinase domain functions independently and can be selectively inactivated by mutations. This bifunctional arrangement couples the epimerization of UDP-GlcNAc to ManNAc with its subsequent phosphorylation, channeling metabolites efficiently into sialic acid biosynthesis.
Regulation by phosphorylation
In simple terms: Other enzymes can add phosphate to the kinase itself, changing its activity.
Protein kinase C (PKC) phosphorylates GNE, modulating its enzymatic activities. This phosphorylation can affect the kinase domain and thus sialic acid production. Such post-translational regulation provides a means to adjust sialic acid biosynthesis in response to cellular signals.
Inhibition and small molecules
In simple terms: Chemicals can block the kinase, which is useful for research and drug development.
Small-molecule inhibitors of human N-acetylmannosamine kinase have been identified and characterized, providing tools to probe sialic acid biology and potential leads for therapeutic intervention. These inhibitors often target the ATP-binding site or substrate pocket, as revealed by crystallography.
Key Genes Involved in GO:0009384 N-acylmannosamine kinase activity
The following genes and proteins are directly associated with N-acylmannosamine kinase activity or its regulation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GNE | Bifunctional enzyme with epimerase and N-acylmannosamine kinase domains; catalyzes ManNAc phosphorylation | Mutations cause hereditary inclusion body myopathy; target for inhibitor design |
| GNE (bacterial homolog) | N-acetylmannosamine kinase in bacteria such as Fusobacterium nucleatum | Model for structural and mechanistic studies |
| PRKCA | Protein kinase C alpha; phosphorylates and regulates GNE | Regulation of sialic acid biosynthesis |
| PRKCB | Protein kinase C beta; may also phosphorylate GNE | Potential regulatory role |
| NANS | Sialic acid synthase; uses ManNAc-6-P downstream | Links kinase activity to sialic acid production |
| NPL | N-acetylneuraminate pyruvate lyase; involved in sialic acid catabolism | Metabolic context |
| SLC35A1 | CMP-sialic acid transporter | Affects sialylation downstream of kinase |
| ST3GAL1 | Sialyltransferase; adds sialic acid to glycans | Readout of pathway activity |
| ST6GAL1 | Sialyltransferase; adds sialic acid to glycans | Readout of pathway activity |
| UGP2 | UDP-glucose pyrophosphorylase; supplies UDP-GlcNAc | Upstream metabolite supply |
| GFPT1 | Glutamine--fructose-6-phosphate transaminase 1; hexosamine pathway | Upstream of UDP-GlcNAc |
| GFPT2 | Glutamine--fructose-6-phosphate transaminase 2; hexosamine pathway | Upstream of UDP-GlcNAc |
| PGM3 | Phosphoglucomutase 3; involved in UDP-GlcNAc synthesis | Upstream supply |
| UAP1 | UDP-N-acetylglucosamine pyrophosphorylase 1 | Upstream supply |
| HK1 | Hexokinase 1; unrelated but phosphorylates sugars | Specificity comparison |
| GCK | Glucokinase; phosphorylates glucose | Specificity comparison |
| NAGK | N-acetylglucosamine kinase; phosphorylates GlcNAc | Related kinase with different substrate |
How Is N-acylmannosamine kinase activity Regulated?
N-acylmannosamine kinase activity is regulated at multiple levels. The bifunctional GNE enzyme is subject to phosphorylation by protein kinase C, which can modulate its kinase activity. Domain-specific mutations can selectively abolish kinase activity without affecting epimerase activity, indicating independent regulation of the two domains. Additionally, feedback inhibition by downstream metabolites such as CMP-sialic acid may influence flux through the pathway. Small-molecule inhibitors can also modulate activity, providing chemical control.
N-acylmannosamine kinase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GNE | Hereditary inclusion body myopathy | Knock-in mouse models with GNE mutations; patient-derived iPSCs |
| GNE | Sialuria | Cell lines overexpressing mutant GNE; metabolic flux analysis |
| GNE | Cancer sialylation | Xenograft models with GNE knockout or overexpression |
| GNE (bacterial) | Bacterial sialic acid scavenging | Bacterial knockout strains; infection models |
| PRKCA | Regulation of sialic acid biosynthesis | PKC inhibitor/activator treatment in cell culture |
Hereditary inclusion body myopathy (HIBM)
Mutations in the GNE gene that impair N-acylmannosamine kinase activity are the primary cause of hereditary inclusion body myopathy (HIBM), also known as GNE myopathy. This adult-onset disorder is characterized by progressive muscle weakness and the presence of rimmed vacuoles in muscle biopsies. The kinase domain mutations reduce sialic acid production, leading to hyposialylation of muscle glycoproteins.
Sialuria
Sialuria is a rare disorder caused by mutations in GNE that lead to overproduction of sialic acid. Some mutations affect the allosteric regulation of the epimerase domain, but the kinase activity may also be altered, contributing to the metabolic imbalance.
Cancer and metastasis
Altered sialylation is a hallmark of cancer, and increased sialic acid production can promote tumor cell migration and immune evasion. N-acylmannosamine kinase activity, as part of the sialic acid pathway, may be upregulated in some cancers, making it a potential target for therapeutic intervention.
Bacterial pathogenesis
Some bacterial pathogens utilize N-acylmannosamine kinase to scavenge and metabolize sialic acid from the host, contributing to colonization and virulence. Structural studies of bacterial kinases aid in the development of antimicrobials.
From N-acylmannosamine kinase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of N-acylmannosamine kinase activity affect sialylation? | GNE knockout cell lines (e.g., HEK293, HeLa) generated by CRISPR |
| Can a specific point mutation in GNE kinase domain cause HIBM? | Knock-in mice or patient iPSCs with GNE point mutations |
| What is the effect of kinase inhibitors on sialic acid production? | Wild-type cells treated with small-molecule inhibitors |
| How does phosphorylation regulate GNE kinase activity? | Point mutations at PKC phosphorylation sites; phospho-mimetic knock-in |
| Can overexpression of GNE enhance sialylation of therapeutic proteins? | CHO cells overexpressing GNE; glycan analysis |
| What is the role of bacterial N-acylmannosamine kinase in pathogenesis? | Bacterial knockout strains; infection models |
How to Study the N-acylmannosamine kinase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Kinase activity assay | Phosphorylation of ManNAc to ManNAc-6-P | Enzyme kinetics, inhibitor screening |
| X-ray crystallography | Three-dimensional structure of kinase domain | Active site mapping, drug design |
| Site-directed mutagenesis | Effect of specific residues on activity | Domain-specific function analysis |
| Metabolic labeling | Sialic acid levels on glycoproteins | Pathway flux, disease modeling |
| CRISPR knockout | Loss-of-function phenotypes | Gene function studies |
| RNA-seq | Transcriptional changes upon kinase modulation | Pathway analysis |
| Proteomics | Protein expression and post-translational modifications | Global effects of kinase inhibition |
| Small-molecule screening | Identification of inhibitors | Chemical biology, therapeutic leads |
Enzymatic assays
Kinase activity can be measured using coupled enzyme assays that detect ADP production or by radiometric assays with 32P-ATP. These methods allow determination of kinetic parameters and inhibitor efficacy.
Structural biology
X-ray crystallography and cryo-EM have been used to solve structures of N-acetylmannosamine kinase from human and bacterial sources, revealing substrate binding and catalytic mechanisms.
Metabolic labeling and glycomics
Sialic acid production can be assessed by metabolic labeling with azido-ManNAc or by mass spectrometry-based glycomics. These methods link kinase activity to downstream sialylation.
CRISPR screening
Genome-wide CRISPR knockout screens can identify genes that modulate sensitivity to N-acylmannosamine kinase inhibitors or that regulate sialic acid levels, uncovering pathway interactions.
How CRISPR Can Be Used to Study GO:0009384 N-acylmannosamine kinase activity
Knockout
CRISPR-Cas9 knockout of GNE eliminates both epimerase and kinase activities, providing a clean background to study sialic acid auxotrophy. Such knockouts are valuable for assessing the requirement of N-acylmannosamine kinase activity in cell growth, signaling, and glycosylation.
Point Mutation
Introducing specific point mutations in the GNE kinase domain (e.g., those found in HIBM patients) via CRISPR prime editing or homology-directed repair allows dissection of kinase-specific functions without affecting the epimerase domain.
Knock-in
Knock-in of tagged GNE (e.g., FLAG or GFP) enables localization and interaction studies. Knock-in of disease-associated mutations in model organisms recapitulates HIBM phenotypes.
Overexpression
Overexpression of wild-type or mutant GNE in mammalian cells can increase sialic acid production, useful for biotherapeutic manufacturing and for studying gain-of-function effects.
How EDITGENE Supports N-acylmannosamine kinase activity Research
Researchers studying N-acylmannosamine kinase activity-related genes often need to determine whether a candidate gene is causally involved in sialic acid metabolism, disease pathogenesis, or drug response. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for N-acylmannosamine kinase activity research.
Frequently Asked Questions About N-acylmannosamine kinase activity
What is N-acylmannosamine kinase activity?
N-acylmannosamine kinase activity (GO:0009384) is the enzyme function that transfers a phosphate from ATP to N-acyl-D-mannosamine, forming N-acyl-D-mannosamine 6-phosphate.
What genes are involved in N-acylmannosamine kinase activity?
The primary human gene is GNE, which encodes a bifunctional enzyme with epimerase and kinase domains. Bacterial homologs also exist.
What is the role of GNE in sialic acid biosynthesis?
GNE catalyzes the epimerization of UDP-GlcNAc to ManNAc and the subsequent phosphorylation of ManNAc, a key step in sialic acid production.
How is N-acylmannosamine kinase activity regulated?
It is regulated by phosphorylation via protein kinase C and by domain-specific interactions. Small-molecule inhibitors can also modulate activity.
What diseases are associated with N-acylmannosamine kinase mutations?
Mutations in GNE kinase domain cause hereditary inclusion body myopathy and may contribute to sialuria and cancer.
What is the structure of N-acetylmannosamine kinase?
Crystal structures of human and bacterial N-acetylmannosamine kinase reveal a conserved active site with ATP and substrate binding pockets.
Can N-acylmannosamine kinase be inhibited?
Yes, small-molecule inhibitors targeting human N-acetylmannosamine kinase have been developed and characterized.
How can I study N-acylmannosamine kinase activity in the lab?
Common methods include enzymatic assays, CRISPR knockout, metabolic labeling, and structural biology.
What is the difference between GNE epimerase and kinase domains?
The epimerase domain converts UDP-GlcNAc to ManNAc, while the kinase domain phosphorylates ManNAc. They can be selectively inactivated.
Why is N-acylmannosamine kinase important for biotechnology?
It is critical for sialylation of therapeutic proteins, and its manipulation can enhance or reduce sialic acid content on glycoproteins.
Conclusion
N-acylmannosamine kinase activity (GO:0009384) is a central enzymatic step in sialic acid biosynthesis, with critical roles in human health and disease. The bifunctional GNE enzyme and its kinase domain have been extensively characterized structurally and functionally, revealing opportunities for therapeutic intervention. CRISPR-based models are powerful tools to dissect the precise contributions of this activity to metabolism, disease, and glycobiology.
References
- 1. Martinez J et al.. 2012. Crystal structures of N-acetylmannosamine kinase provide insights into enzyme activity and inhibition.. J Biol Chem 287(17):13656-65 PMID: 22343627
- 2. Effertz K et al.. 1999. Selective loss of either the epimerase or kinase activity of UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase due to site-directed mutagenesis based on sequence alignments.. J Biol Chem 274(40):28771-8 PMID: 10497249
- 3. Caing-Carlsson R et al.. 2017. Crystal structure of N-acetylmannosamine kinase from Fusobacterium nucleatum.. Acta Crystallogr F Struct Biol Commun 73(Pt 6):356-362 PMID: 28580924
- 4. Hinderlich S et al.. 2001. Biosynthesis of N-acetylneuraminic acid in cells lacking UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase.. Biol Chem 382(2):291-7 PMID: 11308027
- 5. Hinderlich S et al.. 1998. Purification and characterization of N-acetylglucosamine kinase from rat liver--comparison with UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase.. Eur J Biochem 252(1):133-9 PMID: 9523722
- 6. Horstkorte R et al.. 2000. Protein kinase C phosphorylates and regulates UDP-N-acetylglucosamine-2-epimerase/N-acetylmannosamine kinase.. FEBS Lett 470(3):315-8 PMID: 10745088
- 7. Blume A et al.. 2004. Domain-specific characteristics of the bifunctional key enzyme of sialic acid biosynthesis, UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase.. Biochem J 384(Pt 3):599-607 PMID: 15330759
- 8. Hinderlich S et al.. 2017. Small Molecules Targeting Human N-Acetylmannosamine Kinase.. Chembiochem 18(13):1279-1285 PMID: 28346741
